



Disease

Intraabdominal Cancers (Various Types)

Protocol Title

Use of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With End-Stage, Treatment-Resistant Epithelial-Derived Cancer

Principal Investigator

Barry Smith, M.D., Ph.D.

Contact Information:

Barry H. Smith MD, PhD
212-746-1551

Brief Summary of Protocol

This is a Phase I trial to evaluate the safety and toxicity (health risks and side effects) of Rogosin's investigational (not approved by the Food and Drug Administration) mouse kidney cancer cell-containing agarose-agarose macrobeads that are implanted in the abdominal cavity as a proposed biological treatment of patients with end-stage, treatment-resistant cancer.

Potential candidates for this study include males and females, 18 years and older, with end-stage, treatment resistant epithelial-derived cancer (carcinoma) arising originally within the abdominal cavity with expected minimum six-month survival. Individuals with multiple intraabdominal metastases (spread of the cancer from the original tumor) or carcinomatosis (cancer has spread widely throughout the body) or other medical conditions indicating that the procedure would involve an unacceptably high risk for the individual are not eligible to participate.

Treatment Overview (Potential Benefits)

There is no guarantee that participants will receive direct benefit from this study. Participation in this study may add knowledge about the macrobeads that may one day help others with cancer.

IRB Information

WCMC #0407007343
Dr. David Behrman, Chairman
Institutional Review Board
Weill Cornell Medical College
407 East 61st Street
First Floor
New York, NY 10065
Telephone: 646-962-8196